Despite global efforts to control malaria, the illness remains a significant public health threat.
Currently, there is no licensed vaccine against malaria, but an efficacious vaccine would …

Abstract The Malaria Vaccine Symposium occurred at Johns Hopkins University in
Baltimore, MD, USA on April 25th, 2017, coinciding with World Malaria Day and the WHO …

The concept of a malaria vaccine has sparked great interest for decades; however, the
challenge is proving to be a difficult one. Immune dysregulation by Plasmodium and the …

Sanaria Inc. has developed methods to manufacture, purify and cryopreserve aseptic
Plasmodium falciparum (Pf) sporozoites (SPZ), and is using this platform technology to …

The recent availability of significantly increased levels of funding for unmet medical needs in
the developing world, made available by newly created public-private-partnerships, has …

The Plasmodium spp. parasite was identified as the causative agent of malaria in 1880, and
the mosquito was identified as the vector in 1897. Despite subsequent efforts focused on the …

Controlled human malaria infection by blood stage parasite (BSP) inoculation is an
alternative to the well-established model of infection with Plasmodium falciparum …

Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium
falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in …

Since the recent call for a shift from malaria control to eradication, the role of asexual blood
stage vaccines for falciparum malaria, which are not expected to prevent infection, has …

Considerable efforts and funding are available to shift from laboratory experiments to field
trials. Field trials remain the definitive method to assess the real impact of different vaccines …